Document is current
Any future updates will be listed below
-
Authors
Chakraborty, Rajshekhar https://orcid.org/0000-0001-7336-3003
Bhutani, Divaya
Maurer, Mathew S.
Mohan, Meera https://orcid.org/0000-0002-6913-6526
Lentzsch, Suzanne
D’Souza, Anita https://orcid.org/0000-0002-1092-5643
- License Information
-
More Information
Article History
Received: 19 October 2023
Revised: 9 November 2023
Accepted: 16 November 2023
First Online: 27 November 2023
Competing interests
: R.C. reports honoraria for consulting/Advisory board from the following companies: Janssen, Sanofi, and Adaptive Biotech. S.L. has received compensation as a member of Scientific Advisory Boards or Data Monitoring Committees of Janssen, Pfizer, BMS, Adaptive, GSK, Regeneron, Takeda, Sanofi, Oncopetide and Caelum Biosciences. She received research funding from Sanofi and Zentalis and owns royalties for CAEL-101. A.D. reports institutional research funding from Abbvie, Caelum, Janssen, Novartis, Prothena, Regeneron, Takeda, consulting fees from Janssen and Prothena, advisory board fees from BMS, Janssen, Kedrion, and Prothena. MM reports institutional research funding from GlaxoSmithKline, Takeda Pharmaceutical Company, Ionis Pharmaceuticals, Bristol-Myers Squibb (BMS), Celgene Corporation and Amgen Inc.; Advisory board fees: Sanofi. MSM reports research funding from Alnylam, Pfizer, Eidos, Attralus; and personal fees from Alnylam, Astra Zeneca, Ionis, Intellia, and Novo-Nordis.
